Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
Monalizumab in Acute Myeloid Leukemia: NCT06892223 Clinical Landscape Report 2026
16 October 2026
NCT06892223 clinical landscape for Acute Myeloid Leukemia: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
VC-005 in Dermatitis, Atopic: NCT06891040 Clinical Landscape Report 2026
16 October 2026
NCT06891040 clinical landscape for Dermatitis, Atopic: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Plerixafor in Multiple Myeloma: NCT06892119 Clinical Landscape Report 2026
16 October 2026
NCT06892119 clinical landscape for Multiple Myeloma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Fasudil Hydrochloride Hydrate in Ovarian Cancer: NCT06890858 Clinical Landscape Report 2026
16 October 2026
NCT06890858 clinical landscape for Ovarian Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Daratumumab biosimilar (Henlius) in Multiple Myeloma: NCT06895512 Clinical Landscape Report 2026
16 October 2026
NCT06895512 clinical landscape for Multiple Myeloma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Carboplatin in Platinum-Resistant Primary Peritoneal Carcinoma: NCT06890338 Clinical Landscape Report 2026
16 October 2026
NCT06890338 clinical landscape for Platinum-Resistant Primary Peritoneal Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and develop…
9 min read
Orca Q in Multiple Sclerosis, Primary Progressive: NCT06900192 Clinical Landscape Report 2026
16 October 2026
NCT06900192 clinical landscape for Multiple Sclerosis, Primary Progressive: endpoints, sponsor, phase, geography, readouts, asset context and development whi…
9 min read
Iberdomide Hydrochloride in Refractory Multiple Myeloma: NCT06896916 Clinical Landscape Report 2026
16 October 2026
NCT06896916 clinical landscape for Refractory Multiple Myeloma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
TCR-T Cells(Shenzhen University General Hospital) in Acute Myeloid Leukemia: NCT06904859 Clinical Landscape Report 2026
16 October 2026
NCT06904859 clinical landscape for Acute Myeloid Leukemia: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Imetelstat in Hematologic Diseases: ACTRN12625000226404 Clinical Landscape Report 2026
16 October 2026
ACTRN12625000226404 clinical landscape for Hematologic Diseases: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Venetoclax in Acute Myeloid Leukemia: NCT06903702 Clinical Landscape Report 2026
16 October 2026
NCT06903702 clinical landscape for Acute Myeloid Leukemia: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Selinexor in Acute Myeloid Leukemia: NCT06900088 Clinical Landscape Report 2026
16 October 2026
NCT06900088 clinical landscape for Acute Myeloid Leukemia: endpoints, sponsor, phase, geography, readouts, asset context and development white space.